Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2023
In vivo efficacy and PK/PD analyses of zifanocycline (KBP-7072), an aminomethylcycline antibiotic, against Acinetobacter baumannii in a neutropenic murine thigh infection model.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Li, Tan Xiaojuan, Zhou Tian, Chi Shuangshuang, Zhu Yuanju, Liu Qingmei, Chen Ying, Zhang Jay
Аннотация
INTRODUCTION: Zifanocycline (KBP-7072) is a novel aminomethylcycline antibiotic with a broad spectrum of antibacterial activity. This study determined the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of zifanocycline in mice and the optimal PK/PD index for efficacy against Acinetobacter baumannii in a neutropenic murine thigh infection model.
METHODS: Zifanocycline PK properties were characterized in plasma after single-dose subcutaneous injection in healthy mice at doses of 1, 4, 16, 64, and 256 mg/kg. PK/PD analyses were performed with zifanocycline against 8 clinical A. baumannii isolates in a neutropenic murine thigh infection model.
RESULTS: Plasma total and free drug Cmax, AUC0-inf, and AUC0-24 increased with dose, where Cmax of total drug was 0.12-25.2 mg/L, AUC0-inf was 1.13-234 h*mg/L, AUC0-24 was 1.09-225 h*mg/L, and free drug Cmax was 0.03-5.68 mg/L, AUC0-inf was 0.25-52.6 h*mg/L, and AUC0-24 was 0.25-50.5 h*mg/L. MICs of zifanocycline against A. baumannii ranged from 0.06 to 0.5 mg/L, with significant activity against all 8 strains. Average daily doses of zifanocycline to achieve a static, 1-log10 kill, and 2-log10 kill effect were projected to be 6.92, 9.63, and 13.22 mg/kg, and the mean fAUC/MIC ratios were 6.91, 9.10, and 12.60, respectively. AUC/MIC was the optimal PK/PD index of zifanocycline against A. baumannii.
CONCLUSION: The in vivo efficacy results and PK/PD analyses support the design of optimal dosing regimens in clinical studies and assist with determining clinical breakpoints for zifanocycline.
METHODS: Zifanocycline PK properties were characterized in plasma after single-dose subcutaneous injection in healthy mice at doses of 1, 4, 16, 64, and 256 mg/kg. PK/PD analyses were performed with zifanocycline against 8 clinical A. baumannii isolates in a neutropenic murine thigh infection model.
RESULTS: Plasma total and free drug Cmax, AUC0-inf, and AUC0-24 increased with dose, where Cmax of total drug was 0.12-25.2 mg/L, AUC0-inf was 1.13-234 h*mg/L, AUC0-24 was 1.09-225 h*mg/L, and free drug Cmax was 0.03-5.68 mg/L, AUC0-inf was 0.25-52.6 h*mg/L, and AUC0-24 was 0.25-50.5 h*mg/L. MICs of zifanocycline against A. baumannii ranged from 0.06 to 0.5 mg/L, with significant activity against all 8 strains. Average daily doses of zifanocycline to achieve a static, 1-log10 kill, and 2-log10 kill effect were projected to be 6.92, 9.63, and 13.22 mg/kg, and the mean fAUC/MIC ratios were 6.91, 9.10, and 12.60, respectively. AUC/MIC was the optimal PK/PD index of zifanocycline against A. baumannii.
CONCLUSION: The in vivo efficacy results and PK/PD analyses support the design of optimal dosing regimens in clinical studies and assist with determining clinical breakpoints for zifanocycline.